



Disclosures	\$****
I have no disclosures.	
© Gaueta Hutto 2719	💗 Essentia Health





















	ntia by the		
		FY22 (year ended 6/30/2022)	
	Unique Patients	603,938	
	Total encounters	1,759,385	
	Patient days	201,107	
	Surgeries	43,114	Re-7
U i	ED visits	159,920	


Quality recognition








go Forum Community Hospital



Integrated care, close to home



- Rural and mid-urban integrated care system
- Deep commitment to safety, quality and patient experience
- Support coordinated acute care, chronic disease management and preventive medicine
- Create healthier communities for those we are privileged to serve




and the second second

Essentia Health Cancer Center Volumes

- Approximately 3500 new analytic cancer cases annually
- Approximately 45,000 cancer center clinical encounters annually
- Approximately 44,000 infusion center visits annually






History of Cancer Research at Essentia Health 1977 – Founding member of NCCTG - Duluth Clinic 1983 – NCI support awarded – CCOP 2006 – Pediatric clinical trials initiated – COG, partnership with U of M 2010 – Essentia Central (Brainerd) initiates program 2011 – Essentia West (Fargo) initiates program 2014 – NCI support awarded – NCORP 2017 – EHCCRP – Duluth, Hibbing, Virginia, Ashland, Brainerd, Fargo, Fergus Falls, Aitken 2017 – MNCCTN Expands access to multiple small clinics

2019 – NCORP renewed

📦 Essentia Health









How do we decide which studies to open? What is the science? We emphasize NCTN trials via the Alliance and pharma studies via the AFT


- Do we see these patients?
- What are the infrastructure needs?
 - Patient travel
 - Pathology
 - Radiology
 Radiation oncology
- What are the numbers?
 - Desire at least break-even














Commonly	Weather concerns
Cited	Lack of understand about clinical trials
reasons	Lack of trust about a trial
rural	Direct travel expenses
patients	Number of visits required
decline	Too much burden placed on family members
participation	Concern about the agents being tested
participation	Time and distance to travel is too much
	0 5 10 15 20 25 30 35 40
	% respondents (n=33)
ALLIANCE	
	32




























7/1/802 8/1/2022 10/1/2022 11/1/2022 11/1/2022 1/1/2022 2/1/2028 3/1/2028 4/1/2028 5/1/2028	All Dit Hem/One Encounters 86 335 349 397 502 549 722 856 549 722 856 959 1005 1109 1109	85 151 222 344 412 482 588 639 715 725 725 892	11 53 63 107 544 177 204 247 297	172 382 526 754 1056 1178 1434 1632 1838 2034 2238	4000 1500 2500 2500 2500 2500 2500	All Deer	River Hem/Onc Encour	nters		
6/1/2022 77/2028 8/1/2022 5/1/2023	1221 1439 1572 1277	971 1081 1120 1197	348 408 452 510	2642 2878 3164 3454	500				2	




















9

Challenges to rural oncology care and clinical trials Administrative and leadership support Local medical and administrative culture does not value research and clinical investigation Financials Stability of local clinical practice Community engagement and trust



Rural Provider Engagement – Maximizing Local Enrollment

NBTS Survey – Physician importance¹

 Organizational and Physician factors associated with engagement²

I) Adequate research staff/infrastructure

2) Provider Education

3) Direct research involvement- NCORP

Research navigation – local, NBTS, ABTA







	Therease an annual of the second seco
	1 To C in this x Description of the second sec
	Breast Protocols Back to Table of Contents
	ACASE 11000008 BRAND TERM OF CONTINUE
	Adjuvant
	NSABP BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Breast Cancer (TNBC)
	SWOG S1418 Phase III trial to evaluate efficacy and safety of MK-3475 (Pembrolizumab) as adjuvant therapy for TNBC with >/= 1 cm residual invasive cancer or positive lymph nodes after neo-adjuvant chemo
	Alliance A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC I rial
	Advanced/Metastatic
Γ	NRG BR004 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
	ECOG EAY131: Molecular Analysis for Therapy Choice (MATCH) All Solid Tumors
	Cancer Control
	Cancer Control
h	Alliance A221003-PH30E in RevComized Practor PhiloProc IOWATED POST Master Town Robartow with Breact Records Roc Town Alliance A011401: "BWEL' Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment Of Overweight and Obese Women with Early Revact Cancer
	CARE2: Integrated Cancer Repository for Cancer Research

Protocol	Treatment	Elability B = ⊙⊙ ↓	Special Notations	Site Availability
Breast				Back to Top
Alliance A011502 A Randomized Phase ill Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial	Randomization: A&A/placeho one 300 mg tablet daily x 5 years	Inclusion: Women / nen >18 and <70 years of age PER and PR regate, tunor must be node posite or 2- and an one negative. Patients must be regatered: within 18 months of HE Rand VP positive, harmor must be node posite and within 10 years of diagnosis. pAir mole significant operation for another the may must be at least 30 days prior to study registration	Open: 3-2017 Co-Enroll A011401 (BWEL) Aspirin/Placebo provided by study	Open: Duluth Rrainerd Fargo Fargos Fargus Falls
Companion Study: Alliance A211601 Evaluation of manmographic breast density effect of Aspirin	Registration: collect baseline mammogram taken prior to therapy on A011562 Collect mammogram from time coleset to 1 year and then 2 years on therapy on A011502	Exclusion It of ofoce It of otopic It of oto	Research Team Paige Bosshardt Kanin Bohline	Outreach Sites- Please contact study team. <u>Go to Staff Contact</u> List



















C	linical	Enterprise Vi	ability	
		Mission		
		+		
Margin/ROI	+	Viable	Possibly viable	
	-	Possibly viable	Non-viable	
C Essentia Haalih 2022				70




- Payer mix
- CAH reimbursement
- · Sole community provider reimbursement
- PPS reimbursement
- 340b chemotherapy reimbursement
- Strategic and market share growth

• Downstream • Surgery • Pathology/laboratory • Radiology • Radiation oncology







• 66 yo female from Effie, MN (Pop 123)

· Living her retirement dream in Effie.

NCORP site

• Enrolled to EA4181 Obtained CR

